Work

Safety and efficacy of Azer-cel, an allogeneic CD19 CAR T for the treatment of patients with relapsed/refractory non-Hodgkin lymphoma and chronic lymphocytic leukemia not previously exposed to autologous CAR T therapy.

Year: 2026

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2026.44.16_suppl.7012

Authors: Danielle Nicole Blunt, Matthew Ku, Houston Holmes, Nagendraprasad Sungala, Vinay Vanguru, Jean Yared, Scott Solomon, Hannah Rose, Aparna Raval, Grey A. Wilkinson, John Chong Han Byon, Supriya Gupta

Institutions: Royal Adelaide Hospital, St Vincent's Hospital Melbourne, Liverpool Hospital, Royal Prince Alfred Hospital, University of Maryland, Baltimore, Northside Hospital, Barwon Health, UNSW Sydney, University of Minnesota

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7162487971

Cites:

Cited by:

Related to: